ASFA Tenth Special Issue Reframes Therapeutic Apheresis Across 93 Fact Sheets
The American Society for Apheresis has once again turned therapeutic apheresis into a rigorously organized clinical reference, extending the Tenth Edition of its Special Issue with 93 fact sheets and 183 graded, categorized indications. The document is built for day-to-day decision-making, but its reach is broader than a procedural handbook. It functions as a discipline-wide map for when apheresis should be considered, when it remains uncertain, and where evidence no longer supports routine use.
The committee preserved the fact-sheet format that has shaped the series since the Fourth Edition in 2007. Each entry condenses the available evidence for a single disease entity or clinical condition, then translates it into a recommendation framework clinicians can actually use at the bedside. In a field where indications often span hematology, neurology, nephrology, transplantation, and critical care, that structure matters because the technology itself is only as useful as the biologic target it is meant to remove, replace, or modulate.
Evidence Grading Drives the New Edition
This edition continues the committee’s systematic review and evidence-based approach to grading therapeutic apheresis indications. The goal is not merely to compile uses of the procedure, but to classify them with enough precision that a clinician can separate established practice from experimental or selectively useful therapy. Two new fact sheets were added, and several existing indications changed in categorization or grade. Even without a list of every revised indication in the abstracted material, the direction is clear: the evidence base remains active, and recommendations continue to move as newer data accumulate.
Therapeutic apheresis is inherently mechanistic. It can remove pathologic antibodies, circulating immune complexes, plasma proteins, leukocytes, or other disease-mediating components from blood, and it can also provide replacement fluid when needed. The clinical value of the procedure therefore depends on whether the dominant pathology is driven by a circulating factor that can be physically depleted quickly enough to alter the course of illness. In antibody-mediated disease, for example, rapid plasma exchange can create a short-term biologic reset while disease-directed therapy catches up. In disorders where the injurious signal is intracellular, structural, or irreversible, the rationale weakens fast.
The committee’s evidence hierarchy reflects that reality. Apheresis is not a generic rescue maneuver; it is a targeted intervention whose benefit rises or falls with the biology of the condition being treated.
183 Indications, One Common Clinical Problem: Choosing the Right Patient
Across 183 graded and categorized indications, the practical challenge is patient selection. Apheresis can be lifesaving in the right setting, but its procedural burden is substantial and its benefit often depends on timing, disease phenotype, and concurrent therapy. The special issue is designed to keep those judgments anchored in evidence rather than habit, local custom, or procedural familiarity.
This is especially important because therapeutic apheresis spans a wide range of disorders with very different mechanisms. In some diseases, the procedure is used as a bridge, buying time until immunosuppression, targeted biologic therapy, or definitive treatment begins to work. In others, it may be a temporary adjunct with a narrow role, reserved for severe presentations or treatment-refractory disease. The fact-sheet approach helps clinicians see where the evidence supports broad use and where it supports selective use only.
Two new fact sheets in the Tenth Edition signal that the field continues to evolve. New disease frameworks enter the literature, older recommendations are refined, and some uses strengthen while others narrow. A living guideline matters in a procedure-based specialty because treatment pathways change as immunology, critical care, and transplant medicine generate new data. The document’s value lies in tracking that movement without overpromising what the evidence does not yet show.
Why the Fact-Sheet Model Still Works in 2026
The long-running fact-sheet model survives because it translates complexity into clinical order. Each sheet briefly summarizes the evidence for a specific disease, then grades the indication in a way that supports rapid consultation. For physicians, transfusion medicine specialists, apheresis teams, and consultants in subspecialty care, that means a decision can be made with the literature in view rather than from memory alone.
That design also reduces one of the persistent problems in procedural medicine: inconsistent use across institutions. When a therapy is technically demanding, multidisciplinary, and dependent on blood product resources, practice variation can become wide. A stable, evidence-graded reference helps constrain that variation. It also gives clinicians a shared language for discussing uncertain or evolving indications with patients and care teams.
The Tenth Edition retains the central premise that evidence should drive apheresis use, not the reverse. The committee’s charge is to review, update, and categorize indications in human disease, and this edition stays tightly aligned with that mission. The result is not a single headline recommendation but a broad clinical framework for evaluating when apheresis belongs in the treatment plan.
The Clinical Meaning of Ongoing Revisions
Several changes to indications, categorization, or grade are more than editorial adjustments. They imply that the committee found enough new information to move some uses of apheresis closer to, or farther from, routine clinical acceptance. In a field where recommendations can influence device utilization, staffing, blood product management, and referral patterns, even incremental shifts carry practical weight.
For bedside teams, the message is straightforward. Therapeutic apheresis should be deployed where the pathophysiology is tractable, where the evidence supports benefit, and where the clinical situation justifies the invasiveness and resource use. The procedure remains one of the few ways to remove pathogenic circulating material immediately, but immediacy does not guarantee appropriateness. Evidence-based categorization is what keeps that distinction clinically honest.
The Tenth Special Issue does not claim to settle every disputed indication. It does something more durable: it preserves a structured, evidence-graded reference for the field and updates it where the literature has shifted. In a specialty built on rapidly altering circulating factors, the guideline itself has to be equally responsive, and this edition keeps that discipline intact.